Stocks of Blueprint Medicines Corporation (NASDAQ:BPMC) traded higher last session on Wall Street, down -1.52% to $46.65.
According to the data, Blueprint Medicines Corporation (NASDAQ:BPMC) has 19 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $115.00 and a low of $39.00, we find $80.00. Given the previous closing price of $47.37, this indicates a potential upside of 68.88 percent. BPMC stock price is now 3.46% away from the 50-day moving average and -17.41% away from the 200-day moving average. The market capitalization of the company currently stands at $2.92B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 6 analysts have issued a hold rating and 10 have given it a buy rating. Brokers who have rated the stock have averaged $78.06 as their price target over the next twelve months.
With the price target maintained at $41, Wells Fargo recently Upgraded its rating from Underweight to Equal Weight for Blueprint Medicines Corporation (NASDAQ: BPMC). On December 14, 2022, Needham recently initiated its ‘Buy’ rating on the stock quoting a target price of $60, while ‘Oppenheimer’ rates the stock as ‘Perform’.
In other news, Albers Jeffrey W., Director sold 20,000 shares of the company’s stock on Dec 05. The stock was sold for $1,001,800 at an average price of $50.09. Upon completion of the transaction, the Director now directly owns 183,243 shares in the company, valued at $8.55 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 03, CHIEF EXECUTIVE OFFICER Haviland Kate bought 1,100 shares of the business’s stock. A total of $48,378 was incurred on buying the stock at an average price of $43.98. This leaves the insider owning 92,281 shares of the company worth $4.3 million. Insiders disposed of 159,883 shares of company stock worth roughly $7.46 million over the past 1 year. A total of 1.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BPMC stock. A new stake in Blueprint Medicines Corporation shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $105,371,000. EMERALD ADVISERS, LLC invested $14,861,000 in shares of BPMC during the first quarter. In the first quarter, EMERALD MUTUAL FUND ADVISERS TRUST acquired a new stake in Blueprint Medicines Corporation valued at approximately $11,833,000. MOORE CAPITAL MANAGEMENT, LP acquired a new stake in BPMC for approximately $10,579,000. PUTNAM INVESTMENTS LLC purchased a new stake in BPMC valued at around $8,113,000 in the second quarter.
Wednesday’s opening bell rang with an opening price of $47.63 for Blueprint Medicines Corporation (NASDAQ: BPMC). During the past 12 months, Blueprint Medicines Corporation has had a low of $40.78 and a high of $85.67. As of last week, the company has a debt-to-equity ratio of 0.22, a current ratio of 7.00, and a quick ratio of 6.80. The fifty day moving average price for BPMC is $45.09 and a two-hundred day moving average price translates $56.49 for the stock.
The latest earnings results from Blueprint Medicines Corporation (NASDAQ: BPMC) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$2.68, missing analysts’ expectations of -$2.23 by -0.45. This compares to -$2.00 EPS in the same period last year. The company reported revenue of $65.98 million for the quarter, compared to $24.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 172.77 percent. For the current quarter, analysts expect BPMC to generate $43.37M in revenue.
Blueprint Medicines Corporation(BPMC) Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
